Can-Fite’s Namodenoson Achieves 16-Month Control in Phase 2a Pancreatic Study
CANF•Can-Fite completed enrollment in its Phase 2a pancreatic cancer trial of namodenoson, with several patients demonstrating prolonged disease control including one patient on therapy for 16 months. Namodenoson’s mechanism targets RAS, Wnt/β-catenin and NF-κB signaling pathways, reinforcing its differentiated approach and favorable safety profile.
1. Phase 2a Trial Highlights
Can-Fite has completed enrollment in its Phase 2a monotherapy study of namodenoson in pancreatic ductal adenocarcinoma. Several patients have demonstrated prolonged disease control, including one on therapy for approximately 16 months, suggesting durable anti-tumor activity in this aggressive cancer.
2. Differentiated Mechanism of Action
Namodenoson is a selective A3 adenosine receptor agonist that concurrently modulates RAS, Wnt/β-catenin and NF-κB pathways. This multi-pathway approach is designed to induce apoptosis and inhibit tumor growth, addressing KRAS-driven resistance mechanisms present in over 90% of pancreatic cancers.
3. Safety and Regulatory Designations
Across clinical programs involving more than 1,600 patients, namodenoson has shown a favorable safety profile. It holds Orphan Drug Designation for pancreatic cancer in the U.S. and Europe and is also advancing in Phase III hepatocellular carcinoma and Phase IIb NASH trials.
